GILD

Gilead Sciences, Inc. News Headlines

$106.45
*  
1.06
0.99%
Get GILD Alerts
*Delayed - data as of Sep. 30, 2014  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog
9/30/2014 5:10:00 PM - Zacks.com

CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
9/30/2014 5:10:00 PM - Zacks.com

Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
9/30/2014 4:30:00 PM - Zacks.com

4 Predictions For The Fourth Quarter
9/30/2014 9:50:00 AM - Seeking Alpha

Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% - Tale of the Tape
9/30/2014 9:46:00 AM - Zacks.com

Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session - Tale of the Tape
9/30/2014 9:39:00 AM - Zacks.com

Gilead Sciences, Inc. Stock's Stunning New Opportunity
9/30/2014 9:15:02 AM - Motley Fool

Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
9/30/2014 8:36:00 AM - Zacks.com

Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog
9/29/2014 6:50:00 PM - Zacks.com

Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog
9/29/2014 5:55:00 PM - Zacks.com

Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
9/29/2014 5:30:00 PM - Zacks.com

Gilead's HCV Combo Drug Harvoni Secures CHMP Backing - Analyst Blog
9/29/2014 5:20:00 PM - Zacks.com

Nektar/AstraZeneca's Moventig a Step Closer to EU Approval - Analyst Blog
9/29/2014 5:10:00 PM - Zacks.com

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
9/29/2014 9:46:00 AM - Zacks.com

Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb
9/29/2014 8:35:02 AM - Motley Fool

Why Main Street Fails
9/29/2014 5:43:00 AM - Seeking Alpha

Update: European Positive Opinion About Gilead's Harvoni Supports Our Bull Case
9/28/2014 9:35:00 AM - Seeking Alpha

What This Huge George Soros Mistake Can Teach You
9/27/2014 11:35:03 AM - Motley Fool

Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog
9/26/2014 5:20:00 PM - Zacks.com

Alnylam Starts New Study on Cardiac Amyloidosis Patients - Analyst Blog
9/26/2014 5:10:00 PM - Zacks.com

MannKind and Sanofi Complete Afrezza Collaboration Deal - Analyst Blog
9/26/2014 4:45:00 PM - Zacks.com

Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance - Analyst Blog
9/26/2014 4:30:00 PM - Zacks.com

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
9/26/2014 3:20:00 PM - Zacks.com

Is Gilead Still Cheap?
9/26/2014 3:03:00 PM - Seeking Alpha

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
9/26/2014 2:50:00 PM - Zacks.com